Trial Profile
Safety and efficacy of ponatinib in subject with chronic myeloid leukaemia who are resistant to two or more prior tyrosine kinase inhibitors.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2019
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms Pearl
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results (n=35) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology